Posted by Michael Wonder on 07 Dec 2024
Imfinzi granted priority review in the US for patients with muscle-invasive bladder cancer
6 December 2024 - Decision based on NIAGARA Phase 3 trial results which demonstrated a statistically significant and clinically meaningful event-free and overall survival benefit.
AstraZeneca’s supplemental biologics license application for Imfinzi (durvalumab) has been accepted and granted priority review in the US for the treatment of patients with muscle-invasive bladder cancer.
